Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer
- 158 Downloads
Cancer cells surviving in ascites exhibit cancer stem cell (CSC)-like features. This study analyzed the expression of the CSC marker CD133 in the ascites-derived exosomes obtained from patients with unresectable pancreatic cancer. In addition, inverse correlation of CD133 expression with prognosis was examined. Of the 133 consecutive patients, 19 patients were enrolled in the study. Exosomes derived from the malignant ascites demonstrated higher density and wider variation in size than those from non-malignant ascites. Western blot revealed enhanced expression of CD133 in exosomes obtained from patients with pancreatic cancer compared to those obtained from patients with gastric cancer or liver cirrhosis. A xenograft mouse model with malignant ascites was established by intraperitoneal inoculation of human pancreatic cancer cells in nude mice. Results obtained from the human study were reproduced in the mouse model. Statistically significant equilateral correlation was identified between the band intensity of CD133 in western blot and overall survival of patients. Lectin microarray analyses revealed glycosylation of CD133 by sialic acids as the major glycosylation among diverse others responsible for the glycosylation of exosomal CD133. These findings suggest that highly glycosylated CD133 in ascites-derived exosomes as a potential biomarker for better prognosis of patients with advanced pancreatic cancer.
KeywordsPancreatic cancer Exosome Ascites CD133 Glycosylation Prognostic biomarker
We thank Ryuhei Higashi, Yasuko Imamura, and Masako Hayakawa for their able technical assistance. We would like to thank Editage for editing and reviewing this manuscript for English language.
This work was supported by The Promotion and Mutual Aid Corporation for Private Schools of Japan (PMAC) Scholarship Fund for Young Researchers.
Compliance with ethical standards
Conflict of interest
The authors have no potential conflicts of interest to be disclosed.
- 4.Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O’Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J (2009) Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27(33):5660–5669CrossRefGoogle Scholar
- 8.Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N (2012) Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7(10):e46858CrossRefGoogle Scholar
- 9.Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90(12):5002–5012Google Scholar
- 10.Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90(12):5013–5021Google Scholar
- 19.Sato T (1968) A modified method for lead staining of thin sections. J Electron Microsc (Tokyo) 17(2):158–159Google Scholar
- 21.Adelian R, Jamali J, Zare N, Ayatollahi SM, Pooladfar GR, Roustaei N (2015) Comparison of Cox’s regression model and parametric models in evaluating the prognostic factors for survival after liver transplantation in Shiraz during 2000–2012. Int J Organ Transplant Med 6(3):119–125Google Scholar
- 23.van der Pol E, Coumans FA, Grootemaat AE, Gardiner C, Sargent IL, Harrison P, Sturk A, van Leeuwen TG, Nieuwland R (2014) Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 12(7):1182–1192CrossRefGoogle Scholar
- 25.Vaz AP, Ponnusamy MP, Rachagani S, Dey P, Ganti AK, Batra SK. Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells (2014) Br J Cancer 111(3): 486–496Google Scholar
- 26.Miyahara K, Nouso K, Morimoto Y, Kinugasa H, Kato H, Yamamoto N, Tsutsumi K, Kuwaki K, Onishi H, Ikeda F, Nakamura S, Shiraha H, Takaki A, Nakahara T, Miura Y, Asada H, Amano M, Nishimura S, Yamamoto K (2015) Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine. Pancreas 44(4):551–556CrossRefGoogle Scholar